Literature DB >> 16459533

Sirolimus: a new immunosuppressant.

T Mukherjee1, B V Shah.   

Abstract

Though organ transplantation has evolved in many a ways over the years, it is not without the disadvantage of causing rejections. Cyclosporin, azathioprine and corticosteroids are time tested and efficacious; however each is accompanied with its own array of disadvantages. Sirolimus is a relatively new immunosuppressant isolated from a macrolide antibiotic. It may have a beneficial role in prophylaxis of rejection as well as treatment of refractory rejection. It also has antifungal, antitumor and anti-smooth muscle proliferative roles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16459533

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  2 in total

Review 1.  mTOR inhibitors in urinary bladder cancer.

Authors:  R Pinto-Leite; R Arantes-Rodrigues; Nuno Sousa; P A Oliveira; L Santos
Journal:  Tumour Biol       Date:  2016-05-27

2.  A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin.

Authors:  K Ono; T Sato; S Iyama; A Tatekoshi; A Hashimoto; Y Kamihara; H Horiguchi; S Kikuchi; Y Kawano; K Takada; T Hayashi; K Miyanishi; Y Sato; R Takimoto; M Kobune; J Kato
Journal:  Blood Cancer J       Date:  2014-02-07       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.